Panobinostat (LBH589)
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Graft-Versus-Host Disease
Conditions
Graft-Versus-Host Disease
Trial Timeline
Apr 1, 2010 → Jun 1, 2016
NCT ID
NCT01111526About Panobinostat (LBH589)
Panobinostat (LBH589) is a phase 1/2 stage product being developed by Novartis for Graft-Versus-Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01111526. Target conditions include Graft-Versus-Host Disease.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00985946 | Phase 2 | Terminated |
| NCT01111526 | Phase 1/2 | Completed |
| NCT00997399 | Phase 1 | Completed |
| NCT00993642 | Phase 1 | Withdrawn |
| NCT01528501 | Phase 2 | Terminated |
| NCT00699296 | Phase 2 | Terminated |
Competing Products
20 competing products in Graft-Versus-Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alefacept | Astellas Pharma | Phase 2 | 52 |
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 41 |
| SHR0302 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Prednisone + Jakavi(ruxolitinib) + Prednisone | Novartis | Phase 2 | 52 |
| PredEver | Novartis | Phase 2 | 52 |
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 33 |
| LBH589 + Methylprednisolone | Novartis | Phase 2 | 52 |
| Filgrastim | Amgen | Pre-clinical | 22 |
| AMG 592 | Amgen | Phase 1 | 32 |
| AMG 592 | Amgen | Phase 1 | 32 |
| BMS-986004 + Sirolimus + Tacrolimus | Bristol Myers Squibb | Phase 1 | 32 |
| Belumosudil (KD025) | Sanofi | Phase 2 | 51 |
| Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QD | Sanofi | Phase 2 | 51 |
| AAT + Placebo | CSL | Phase 2/3 | 64 |
| Ruxolitinib + Methylprednisolone | Incyte | Phase 2 | 49 |
| Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF) | Incyte | Phase 3 | 74 |
| Itacitinib + Corticosteroids | Incyte | Phase 1/2 | 38 |
| Ruxolitinib | Incyte | Pre-clinical | 20 |
| Itacitinib + Corticosteroid | Incyte | Phase 1 | 30 |
| INCA034176 | Incyte | Phase 1/2 | 38 |